Alcon Canada Strengthens Its Commitment to Astigmatic Patients With TOTAL30 for Astigmatism Expanded Parameters
Baird Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $108
Stifel Maintains Alcon(ALC.US) With Buy Rating, Maintains Target Price $100
A Quick Look at Today's Ratings for Alcon(ALC.US), With a Forecast Between $91.6 to $107
Baird Maintains Outperform on Alcon, Raises Price Target to $108
Analysts Conflicted on These Healthcare Names: Agilon Health (AGL), AN2 Therapeutics, Inc. (ANTX) and Alcon (ALC)
Alcon Full Year 2024 Earnings: EPS Beats Expectations
Express News | Alcon AG : Jefferies Raises Target Price to $110 From $100
Earnings Call Summary | Alcon(ALC.US) Q4 2024 Earnings Conference
Alcon Projects $10.2B-$10.4B Revenue in 2025 With Strong Product Launches
Express News | Alcon Shares Are Trading Higher After the Company Reported Better-than-expected Q4 Financial Results
Express News | Alcon CEO on Call About Tariffs: We Manufacture Locally in Our Markets, We Have to See What Happens
Express News | Alcon CEO on Call: Not Planning Price Increases, We Think We Got the Price Right
A Quick Look at Today's Ratings for Alcon(ALC.US), With a Forecast Between $91.84 to $106
RBC Flags Potential 'Small' Downgrade to Alcon Consensus After FY25 Guidance
Alcon Analyst Ratings
Alcon Logs Higher FY24 Net Income, Sales
Alcon | 20-F: FY2024 Annual Report
Alcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say
Alcon's Strong Q4 Performance and Market Share Gains Reinforce Buy Rating Despite Lower 2025 Guidance